Loading institutional data...
Loading institutional data...
No institutional (13F) filings cover this company, so the Overview and 13F tabs are thin. Everything drawn from its SEC filings is here.
Loading snapshot...
Loading financials...
Loading valuation...
Loading analysis...
Loading dividends & returns...
Loading capital allocation...
Loading debt & leverage...
Loading performance...
Loading peer comparison...
Ranked against 20 sector peers with collected financials. Valuation from latest close × latest fiscal-year fundamentals; 13F conviction as of 2026-09-30.
Percentile is “goodness” within the peer set (100 = best). For valuation and leverage that means cheaper / less-levered ranks higher.
| Company | Mkt cap ▼ | P/E | EV/EBITDA | P/S | Rev gr | Gross | Net | ROE | ROIC | Net D/EBITDA | 13F |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LASR | $2.1B | — | — | 8.2× | 31.6% | 29.8% | -9.0% | -10.3% | -10.3% | — | 42 |
| SEDG | $1.8B | — | — | 1.6× | 31.4% | 16.6% | -34.2% | -94.8% | -94.8% | — | 58 |
| PLAB | $1.6B | 12.1× | 4.0× | 1.9× | -2.0% | 35.3% | 16.1% | 11.6% | 11.6% | -1.7× | 76 |
| SKYT | $1.6B | 13.3× | 54.1× | 3.6× | 29.2% | 19.7% | 26.9% | 63.3% | 29.3% | 5.9× | 1 |
| ICHR | $1.5B | — | — | 1.5× | 11.6% | 9.3% | -5.6% | -8.0% | -6.7% | — | 55 |
| SHLS | $1.2B | 36.0× | 17.2× | 2.5× | 19.1% | 35.0% | 7.1% | 5.6% | 5.6% | -0.1× | 41 |
| AMBQ | $1.2B | — | — | 15.9× | -4.7% | 44.3% | -50.3% | -22.4% | -22.4% | — | 17 |
| DQ | $729M | — | — | 1.1× | -35.3% | -20.7% | -25.6% | -3.9% | -3.9% | — | 11 |
| AOSL | $696M | — | 65.7× | 1.0× | -2.5% | 22.3% | -6.2% | -5.3% | -5.3% | — | 39 |
| CSIQ | $629M | — | 12.8× | 0.1× | -6.6% | 18.3% | -1.9% | -3.7% | -0.9% | 11.8× | 29 |
| JKS | $452M | — | — | 0.1× | -25.9% | 2.2% | -6.8% | -28.3% | -28.3% | — | 13 |
| INDI | $382M | — | — | 1.8× | 0.3% | 39.9% | -65.8% | -40.0% | -20.1% | — | 39 |
| NVEC | $376M | 24.7× | 22.8× | 14.3× | 1.8% | 78.7% | 57.7% | 26.1% | 26.1% | -0.1× | 23 |
| MRAM | $332M | — | — | 6.0× | 9.5% | 51.2% | -1.1% | -0.9% | -0.8% | — | 17 |
| LAES | $331M | — | — | 18.1× | 66.2% | 47.3% | -187% | -7.4% | -7.4% | — | 18 |
| MX | $180M | — | — | 1.0× | -8.9% | 17.6% | -16.6% | -12.0% | -10.1% | — | 4 |
| VLN | $164M | — | — | 2.3× | 22.1% | 62.4% | -44.7% | -30.1% | -30.1% | — | — |
| QUIK | $160M | — | — | 11.6× | -29.9% | 22.0% | -108% | -65.9% | -58.2% | — | 16 |
| GSIT | $152M | — | — | 6.0× | 22.4% | 54.5% | -52.7% | -16.2% | -16.2% | — | 13 |
| ALMU | $146M | — | — | 32.6× | -4.4% | 35.2% | -205% | -16.1% | -16.1% | — | 15 |
| RBCN | $45M | — | — | 12.4× | -11.7% | 40.1% | 26.1% | 29.2% | 19.5% | — | — |
Peers = companies sharing RBCN's sector (Semiconductors & Related Devices) with collected SEC financials. Multiples use the most recent end-of-day close and latest fiscal-year fundamentals (trailing, not forward). Missing cells mean the peer never reported that line item, has no collected price, or has a non-positive denominator. Not investment advice.
Solve the discounted cash flow backwards, then stress-test the assumptions.
The same 1 year as the 3-yr average, with the stock compensation of those years charged as a cost. Shares issued to employees are real dilution, so this asks what the business generates for existing holders.
To be worth $4.76 today, the market must believe free cash flow compounds 53.9%/yr for a decade (off $96K on the SBC-adjusted basis).
On the basis ($295K) the requirement is 36.6%/yr. The difference is what charging stock compensation costs.
Default is 10.3% — this company's computed cost of capital (computed WACC), the same rate the Analysis tab discounts at.
2-stage DCF · 0.01B shares (market data) · net debt $1K
Reverse DCF: rather than guessing a fair value, we solve for the growth the current price implies, then you stress-test the assumptions. Enterprise value of the FCF stream, less net debt, ÷ shares. Educational — not a recommendation.
What the company returns to shareholders — and whether it's covered by cash.
No dividend to cover. Last year: $0 dividends + $0 buybacks = $0 returned.
Yields use the latest fiscal-year dividends/buybacks over current market cap. Dividends and buybacks from the SEC cash-flow statement; payout coverage vs net income and free cash flow. Educational — not a recommendation.
How management deployed cash over 10 years — and what it earned on reinvestment.
A reinvestment story — most cash went back into growth rather than to shareholders.
Reinvestment has been productive — operating income grew well per dollar put in. Current ROIC on all capital: 19%. Rough measure (includes maintenance capex).
Cash uses aggregated from the SEC cash-flow statement over 10 fiscal years. "Return on reinvestment" is a rough proxy — operating-income change ÷ cumulative CapEx + M&A — and includes maintenance capex. Educational — not a recommendation.
How much the company owes, how it's trended, and how comfortably it's serviced.
Insufficient EBITDA/debt history.
Green ≤ 1.5× · amber ≤ 3× · red > 3× (leverage relative to cash earnings).
Interest is easily covered by operating profit. Effective rate ~2.5% on $1.6M of debt.
Cash of $1.6M fully covers short-term debt of $25K.
Mostly long-term debt (balance-sheet current vs non-current split). A year-by-year maturity schedule wasn't disclosed for this issuer.
Debt, cash, interest and equity from the SEC balance sheet & income statement. Effective rate = interest ÷ average debt. Educational — not a recommendation.
EOD close · as of 2026-10-30
How a revenue dollar becomes profit — FY2022
Dividends and buybacks are cash paid out, shown here against the same year's profit for scale — not funded from it.
Each value shows its share of revenue below it (common-size).
| Line Item | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.6M 100.0% | $4.1M 100.0% | $3.6M 100.0% | $3.5M 100.0% | $3.9M 100.0% | $5.0M 100.0% | $19.6M 100.0% | $23.8M 100.0% | $45.7M 100.0% | $41.5M 100.0% |
| Cost of Revenue | $2.1M 59.9% | $2.8M 68.9% | $2.6M 72.1% | $2.4M 69.3% | $3.9M 99.6% | $10.6M 209.2% | $7.5M 38.2% | $47.0M 197.2% | $75.4M 165.0% | $63.4M 152.8% |
| Cost of Products | — | — | — | — | — | $10.6M 209.2% | $45.6M 232.5% | $47.0M 197.2% | $75.4M 165.0% | $63.4M 152.8% |
| Gross Profit | $1.4M 40.1% | $1.3M 31.1% | $1.0M 27.9% | $1.1M 30.7% | $16K 0.4% | -$5.5M -109.2% | -$26.0M -132.5% | -$23.1M -97.2% | -$29.7M -65.0% | -$21.9M -52.8% |
| Research & Development | $662K 18.5% | $662K 16.3% | — | — | $122K 3.1% | $962K 19.1% | $2.5M 13.0% | $2.2M 9.3% | $1.9M 4.1% | $2.3M 5.5% |
| Selling, General & Admin | $2.3M 65.4% | $2.1M 52.5% | $1.9M 53.7% | $2.5M 72.3% | $2.3M 58.0% | $4.5M 89.4% | $7.7M 39.2% | $9.6M 40.3% | $9.9M 21.6% | $8.6M 20.8% |
| Operating Income | $585K 16.3% | -$464K -11.4% | $530K 14.7% | -$1.3M -35.5% | $635K 16.4% | -$17.9M -355.4% | -$62.7M -319.5% | -$75.9M -318.9% | -$43.6M -95.5% | -$34.9M -84.0% |
| Interest Expense | $39K 1.1% | — | — | — | — | — | $99K 0.5% | $109K 0.5% | $95K 0.2% | $95K 0.2% |
| Interest & Investment Income | $105K 2.9% | $5K 0.1% | $108K 3.0% | $460K 13.0% | $361K 9.3% | $116K 2.3% | $73K 0.4% | $71K 0.3% | $86K 0.2% | $51K 0.1% |
| Other Income (Expense), net | $334K 9.3% | $5K 0.1% | -$1.6M -43.7% | $125K 3.5% | $352K 9.1% | $161K 3.2% | -$385K -2.0% | -$1.9M -8.0% | -$302K -0.7% | -$627K -1.5% |
| Pretax Income | $919K 25.6% | -$459K -11.3% | -$710K -19.6% | -$1.1M -31.9% | $987K 25.5% | -$17.8M -352.2% | -$63.1M -321.5% | -$77.9M -326.9% | -$43.9M -96.1% | -$35.5M -85.5% |
| Income Tax Expense | — | — | $13K 0.4% | $22K 0.6% | $24K 0.6% | $88K 1.7% | -$223K -1.1% | -$26K -0.1% | $78K 0.2% | -$5.2M -12.4% |
| Net Income | $935K 26.1% | -$730K -18.0% | -$1.1M -29.4% | -$1.1M -32.5% | $963K 24.8% | -$17.9M -353.9% | -$62.9M -320.3% | -$77.8M -326.8% | -$44.0M -96.3% | -$30.4M -73.1% |
| Per Share | ||||||||||
| EPS (Basic) | — | — | -$0.43 | -$0.42 | $0.35 | -$6.60 | -$23.86 | -$2.98 | -$1.70 | -$1.35 |
| EPS (Diluted) | — | — | -$0.43 | -$0.42 | $0.35 | -$6.60 | -$23.86 | -$2.98 | -$1.70 | -$1.35 |
| Weighted Avg Shares (Basic) | 2.4M | 2.4M | 2.5M | 2.7M | 2.7M | 2.7M | 2.6M | 26.2M | 25.8M | 22.6M |
| Weighted Avg Shares (Diluted) | 2.5M | 2.4M | 2.5M | 2.7M | 2.7M | 2.7M | 2.6M | 26.2M | 25.8M | 22.6M |
Source: SEC EDGAR XBRL filings (annual, fiscal year). Quarterly flow items are derived from cumulative filings; balance-sheet figures are as-of each period end. Ratios and margins are computed, not reported.
Total return (dividends reinvested) vs the market, from quarter-end prices.
Above 0 = ahead of the S&P 500 since the window start; below 0 = behind. Rising means it's pulling ahead.
How far the stock fell below its prior peak. Deeper, longer drawdowns = a rougher ride to the same return.
Quarter-end, dividend-adjusted (total return). Beta & volatility from quarterly returns (annualized). Benchmark is the S&P 500 (SPY total return). Annual returns compound the quarters ending in each calendar year; the first and last years in a window may be partial. Past performance doesn't predict future results.
EOD close · as of 2026-10-30
Where each multiple sits in its own 11-yr range · 100th pct blended
Dot = today · shaded = middle 50% · line = median. Lower percentile = cheaper vs its own 11-yr history.
Is the profit real, and how strong is the balance sheet?
FY2022 · every deduction from revenue to net income
DuPont — the three levers
ROE 29% against ROIC 19% — 10% of the return on equity comes from leverage and buybacks rather than from the operating business.
Equity is the year-end figure. On average equity over the two year-ends, ROE is 5.7% — the two diverge when buybacks or issuance move equity during the year.
What the company owes vs. what it holds
This shows debt/cash structure and net leverage. The year-by-year maturity schedule is on the Debt & Leverage tab.
Latest year: profit growth vs revenue growth
High operating leverage: profit moved 19.4× as fast as sales — great in an upturn, painful in a downturn.
Each line as % of revenue — the trend in color
| % of revenue | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|---|
| Cost of Revenue | 197.2 | 38.2 | 209.2 | 99.6 | 69.3 | 72.1 | 68.9 | 59.9 |
| Gross Profit | -97.2 | -132.5 | -109.2 | 0.4 | 30.7 | 27.9 | 31.1 | 40.1 |
| R&D | 9.3 | 13.0 | 19.1 | 3.1 | — | — | 16.3 | 18.5 |
| SG&A | 40.3 | 39.2 | 89.4 | 58.0 | 72.3 | 53.7 | 52.5 | 65.4 |
| Operating Income | -318.9 | -319.5 | -355.4 | 16.4 | -35.5 | 14.7 | -11.4 | 16.3 |
| Income Tax | -0.1 | -1.1 | 1.7 | 0.6 | 0.6 | 0.4 | — | — |
| Net Income | -326.8 | -320.3 | -353.9 | 24.8 | -32.5 | -29.4 | -18.0 | 26.1 |
Green = margin-favorable vs the row's own range · red = unfavorable.
The metrics that matter, over time
A 30-second read on RBCN: price, valuation and headline fundamentals from SEC filings. The four questions at the top of the page are where the judgements live.
Cost of capital cannot be computed, so the spread is unknown.
| Fiscal year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| FY2013 | -52.8% | -84.0% | -73.1% |
| FY2014 | -65.0% | -95.5% | -96.3% |
| FY2015 | -97.2% | -318.9% | -326.8% |
| FY2016 | -132.5% | -319.5% | -320.3% |
| FY2017 | -109.2% | -355.4% | -353.9% |
| FY2018 | 0.4% | 16.4% | 24.8% |
| FY2019 | 30.7% | -35.5% | -32.5% |
| FY2020 | 27.9% | 14.7% | -29.4% |
| FY2021 | 31.1% | -11.4% | -18.0% |
| FY2022 | 40.1% | 16.3% | 26.1% |
Leverage and buybacks account for 10 points of the 29% return on equity in FY2022. The business earns 19% on the capital it employs; the rest is balance sheet.
ROE is on average equity; ROIC is NOPAT over average invested capital (debt plus equity less excess cash). The gap is not a single adjustment.
No material counter-signal in the checked set: ROIC vs WACC spread, 5-year spread history, gross margin trend, operating margin trend, net margin against 3 years ago, revenue growth, ROIC ex-goodwill gap.
Missing from our data, so excluded from this answer: tax_rate.
Fewer than three profitable years with a cash flow statement, so cash conversion cannot be judged.
No material counter-signal in the checked set: FCF / net income over 3 and 5 years, Sloan accruals, SBC as a share of revenue, SBC as a share of operating cash flow, SBC-adjusted free cash flow, free cash flow per diluted share, buybacks against SBC issued, capex vs depreciation, free cash flow against revenue, share count since the first year on file, cash conversion cycle (DSO, DIO, DPO), receivables growth against revenue growth.
Missing from our data, so excluded from this answer: 3 years of cash flow.
Debt is present but there is no positive EBITDA or no reported interest expense, so coverage cannot be measured.
Balance sheet at 2022-12-31. Undrawn revolving credit is not shown: the tag is collected but not yet mapped through to the API.
No material counter-signal in the checked set: net debt / EBITDA, interest coverage, stressed coverage, maturity schedule vs cash and one year of FCF, liquidity ratios.
Missing from our data, so excluded from this answer: ebitda, interest_expense.
At $4.76, free cash flow must compound 53.86%/yr for 10 years. It has no positive compounding record after stock compensation to compare against, though across a reporting-basis change.
The percentile ranks the FISCAL-YEAR point, because the distribution behind each strip is built from fiscal-year closes — ranking a TTM figure inside it would compare two different bases. TTM basis: TTM.
The achieved growth rate spans a reporting-basis change in FY2020, so part of it measures the restatement rather than the business.